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Genomic Analyses of Breast Cancer 
Progression Reveal Distinct Routes 
of Metastasis Emergence
Anne Bruun Krøigård1,2, Martin Jakob Larsen1,2, Charlotte Brasch-Andersen1,2,  
Anne-Vibeke Lænkholm3, Ann S. Knoop4, Jeanette Dupont Jensen5, Martin Bak6, 
Jan Mollenhauer7,8, Mads Thomassen1,2,7 & Torben A. Kruse1,2,7
A main controversy in cancer research is whether metastatic abilities are present in the most advanced 
clone of the primary tumor or result from independently acquired aberrations in early disseminated 
cancer cells as suggested by the linear and the parallel progression models, respectively. The genetic 
concordance between different steps of malignant progression is mostly unexplored as very few studies 
have included cancer samples separated by both space and time. We applied whole exome sequencing 
and targeted deep sequencing to 26 successive samples from six patients with metastatic estrogen 
receptor (ER)-positive breast cancer. Our data provide support for both linear and parallel progression 
towards metastasis. We report for the first time evidence of metastasis-to-metastasis seeding in breast 
cancer. Our results point to three distinct routes of metastasis emergence. This may have profound 
clinical implications and provides substantial novel molecular insights into the timing and mutational 
evolution of breast cancer metastasis.
Next generation sequencing (NGS) has been extensively applied to catalogue the mutational landscapes of large 
numbers of primary breast tumors1–5 but the mutational evolution through breast cancer progression and the 
timing of metastasis have remained elusive. In pancreatic6 and colorectal cancer7, distant metastasis has been 
reported a late event in molecular time. Two studies of single breast cancer patients have provided support for 
a linear progression model, where metastases emerge from late occurring advanced clonal subpopulations8,9. 
Opposed to this, the parallel progression model suggests early metastasis seeding and independent acquisition 
of mutations in the primary tumor and the disseminated cells10. The parallel progression model implies that 
cancer is a systemic disease at an early time point and for this progression pattern systemic adjuvant treatment is 
necessary11. In general, close genetic ties between primary tumor and metastasis have been considered indicative 
of linear progression, whereas genetic divergence is interpreted as evidence of parallel progression12.
In agreement with Naxerova et al.12, we consider linear progression as metastasis seeding from the most 
advanced clone of the primary tumor. By contrast, parallel progression, is considered to have taken place if more 
advanced clones within the primary tumor can be found in addition to the clone giving rise to the metastasis.
A third mechanism, the concept of metastasis-to-metastasis seeding, the cascade hypothesis13, was proposed 
in 1975. Until recently, this phenomenon has not been proven by high resolution studies. In prostate cancer, very 
recent NGS studies including four14 and ten15 primary tumor-metastasis pairs identified a subset of tumors with 
evidence for metastasis-to-metastasis seeding.
In this study, we provide evidence of three distinct routes of breast cancer progression and find diverse pat-
terns of progression among and even within patients.
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Results
Large variation in mutational concordance between the different steps of metastatic progression. 
We analyzed a set of six breast cancers with matched premalignant, synchronous axillary lymph node metas-
tases (sALN) and/or asynchronous distant metastases (aDM) (Table 1, Supplementary Table S1). aDM from 
four of the patients were biopsied with a relapse time between 1.82–4.05 years. Paired-end exome sequenc-
ing (Supplementary Table S2) was applied to the 26 samples, followed by identification of potential somatic 
mutations by using the union of results from nine different somatic variant callers. Targeted deep sequencing 
(200–613× coverage) (Supplementary Table S3) was used to increase data quality followed by stringent filtering of 
somatic mutations in the coding region (44–531 somatic mutations per patient). A full table of somatic mutations 
and their allele frequency is included (Supplementary Tables S4–S9).
Large variation in mutational concordance was observed between the different steps of malignant progression 
of the studied patients (Supplementary Fig. S1). Furthermore, deep sequencing enabled us to detect small sub-
clonal populations within each tumor sample, visualized by frequency plots.
Bubble Tree analysis16 was performed to estimate tumor purity, ploidy and clonality, inferred from exome 
sequencing data (Supplementary Figs S2–S21). The tumor purity of the samples, based on these analyses, ranges 
between 0.24–0.95 (Supplementary Table S2).
Linear progression towards metastasis. Patients P15, P46 and P123 displayed 42, 430 and 86 mutations 
in the primary tumors, of which 29 (69%), 426 (99%) and 80 (93%), respectively were shared with the match-
ing metastases (Supplementary Fig. S1). All three cases showed relatively high genetic concordance between 
successive steps of cancer progression and thus, the cancer genomes of these patients presented fairly stable. 
Phylogenetic analyses, depicted by mutational frequency plots, provided straight forward evidence that metasta-
ses in these three cases originated from the most recent and advanced subclone of the primary tumor in accord-
ance with the linear progression model (Fig. 1a–c). This is supported by the purification of subclonal mutations 
i.e. increased mutation frequencies in the metastases of P 15 and 46, while no subclones appeared in P123.
Interestingly, the pre-invasive sample of P46 has a number of mutations that are not found in the primary 
tumor. These subclonally occurring mutations in DCIS are most likely present in a different subclone than the one 
giving rise to the invasive lesion, depicted as the turquoise subclone within the DCIS in Fig. 1b.
Co-occurrence of linear and parallel progression towards metastasis. Patient P8 and P11 displayed 
diverse models of metastatic spread (Fig. 2a,b). In both patients, one metastasis arose in accordance with the lin-
ear progression model and the other in accordance with the parallel progression model. In P8, the aDM emerged 
linearly, i.e. from the most recent subclone within the primary tumor. By contrast, the sALN disseminated in 
accordance with the parallel progression model, as the metastasis originated from an earlier stage of primary 
tumor evolution as a number of mutations subclonally occurring in the primary tumor are not present within 
the sALN. Subclonal mutations in the primary tumor constituted complete clonal events in the metastases. This 
purifying effect, revealed by mutation frequencies, confirms the subclonal origin of the metastases. In P11 the 
sALN emerged linearly, while the aDM developed in accordance with the parallel progression model. The aDM 
contained only a few of the subclonally occurring mutations in the primary tumor. It harbored predominantly the 
complete, early mutations as well as 77 new mutations, which are exclusive to this metastasis, revealing parallel 
progression of this metastasis (Fig. 2b). Thus, the two metastases originated from two different cell populations 
within the primary tumor, supported by the fact that no mutations are shared solely by the two different metasta-
ses. In both P8 and P11 a substantial amount of additional mutations were found in the metastases. Parallel pro-
gression of metastasis, indicated by high mutational discordance, bears profound clinical implications as clonal 
divergence between primary tumors and metastases opens potentially broad windows for therapy escape.
Metastasis-to-metastasis seeding. Most remarkably, patient P4 displayed somatic mutational patterns 
revealing seeding of the aDM from the sALN as 36 mutations, not detectable in the primary tumor, were shared 
by the two metastases (Fig. 3). Further, 26 additional mutations are found in the aDM, revealing high muta-
tional discordance between primary tumor and metastatic lesions in this case. The founder cell of the aDM dis-
seminated from the sALN, supported by the fact that all mutations shared between the aDM and the primary 
P
Number of tumor samples
Time to relapseDCIS Primary tumor sALN aDM
4 2 1 1 (liver) 1.82 years
8 2 1 1 1 (contr. LN) 4.05 years
11 1 1 1 (liver) 2.57 years
15 1 1 (bone) 3.90 years
46 1 1 1
123 1 1 1
Table 1.  Samples included in the study. P: patient. DCIS: ductal carcinoma in situ. sALN: synchronous 
axillary lymph node metastasis. aDM: asynchronous distant metastasis. Contr. LN: contralateral lymph node 
metastasis.
www.nature.com/scientificreports/
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Figure 1. Linear progression of metastases. Allele frequency plots and phylogenetic trees for (a) P15, (b) 
P46 and (c) P123. Allele frequency plots, based on targeted deep sequencing data, comparing frequencies of 
validated somatic mutations in the coding region between different steps of malignant progression. Each dot 
represents a somatic non-synonymous, splicing or synonymous somatic mutation. The color code indicates 
the step at which the mutation appears for the first time. Dots in blue, red, green and purple depict mutations 
appearing for the first time in pre-invasive tissue, primary tumor, synchronous axillary lymph node metastases 
(sALN) and asynchronous distant metastasis (aDM), respectively. The arrows indicate the level corresponding 
to the diploid, heterozygous allele frequency of the sample, derived from Bubble Tree analysis. Phylogenetic 
trees depict the clonal evolution through cancer progression. An increase in color intensity reflects the 
acquisition of additional somatic mutations.
www.nature.com/scientificreports/
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Figure 2. Diverse patterns of progression within patients. Allele frequency plots and phylogenetic trees 
for (a) P8 (b) P11. Allele frequency plots, based on targeted deep sequencing data, comparing frequencies of 
validated somatic mutations in the coding region between different steps of malignant progression. Each dot 
represents a somatic non-synonymous, splicing or synonymous somatic mutation. The color code indicates 
the step at which the mutation appears for the first time. Dots in blue/turquoise, red, green and purple depict 
mutations appearing for the first time in pre-invasive tissue, primary tumor, sALN and aDM, respectively. The 
arrows indicate the level corresponding to the diploid, heterozygous allele frequency of the sample, derived 
from Bubble Tree analysis. Phylogenetic trees depict the clonal evolution through cancer progression. An 
increase in color intensity reflects the acquisition additional somatic mutations.
www.nature.com/scientificreports/
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tumor are also found in the sALN. To our knowledge, this is the first time that metastasis-to-metastasis seeding 
is reported for breast cancer.
Rather surprisingly, some of the mutations originating from the primary tumor in P4 appeared with 
a similar frequency pattern in primary tumor and metastases. Such pattern could emerge as a result of com-
plex copy number aberrations. To explore this hypothesis we conducted micro array analysis on the data 
(Supplementary Figs S22 and S23). Indeed, this revealed very few regions to be diploid. Hence, this cancer cell 
population has a more complex pattern of somatic copy number mutations and hyperploidy with varying number 
of point mutations within the different alleles explaining the retained mutation frequencies in the metastases. 
Another explanation to the phenomenon could be that not a single cell but a cluster of non-identical primary 
tumor cells founded the metastatic lesion as recently suggested by others17,18.
Mutations found exclusively in metastases. We finally analyzed the mutant gene sets derived from 
the studies. Mutations found exclusively in the metastases (Supplementary Table S10) affected the CREBBP and 
PPP2R1A genes which are already included as cancer-related genes in the Catalogue Of Somatic Mutations In 
Cancer (COSMIC) Cancer Gene Census list (http://cancer.sanger.ac.uk/cancergenome/projects/census/). The 
Figure 3. Metastasis to metastasis seeding. Allele frequency plot and phylogenetic tree for (a) P4. The 
allele frequency plots, based on targeted deep sequencing data, compare frequencies of validated somatic 
mutations in the coding region between different steps of malignant progression. Each dot represents a somatic 
non-synonymous, splicing or synonymous somatic mutation. The color code indicates the step at which the 
mutation appears for the first time. Dots in red/orange, green and purple depict mutations appearing for the 
first time in primary tumor, sALN and aDM, respectively. The arrows indicate the level corresponding to the 
diploid, heterozygous allele frequency of the sample, derived from Bubble Tree analysis. The phylogenetic tree 
depicts the clonal evolution through cancer progression. An increase in color intensity reflects the acquisition 
additional somatic mutations.
www.nature.com/scientificreports/
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CREBBP gene is an epigenetic modifier acting as a transcriptional coactivator through acetylation of histone 
proteins and has been suggested as tumor suppressor19. Further, BCL6B and ZNF185 were among the genes with 
exclusive mutations in the metastases. The BCL6B gene has recently been reported as novel tumor and metastasis 
suppressor in hepatocellular carcinoma20. Stable expression of the BCL6B gene in hepatocellular cell lines is found 
to suppress cell migration and invasion and significantly reduce the incidence and severity of lung metastases in a 
mouse model20. The ZNF185 gene has been suggested to function as a tumor suppressor and has been associated 
with metastatic progression in colon and prostate cancer21,22.
Discussion
We are to the best of our knowledge, the first to report a detailed description of the mutational evolution through 
successive steps of breast cancer progression with establishment of the clonal origin of metastases, revealing 
complex patterns of metastatic spread. Linear progression from the primary tumor is a common event observed 
in 5 out of 6 cases. However, two of these cases showed evidence for the co-occurrence of parallel progression 
from early seeding events. It cannot be ruled out that such co-occurrence is more frequent than suggested by the 
presented cases, because for each of the three cases in which exclusively linear progression was observed only a 
single metastasis was analyzed. Further, it cannot be ruled out that additional low-frequency subclones, below 
our detection limit, may have escaped our attention, especially in the few samples with a tumor content around 
25%. However, in these samples the malignant cells have been sequenced at a depth of around 20× and somatic 
variants have been called by a non-conservative, sensitive method followed by deep sequencing. This allow us 
to detect medium frequency subclones. We provide evidence of parallel progression of two sALN metastases 
(P4 and P8) and two aDM (P4 and P11) and these findings are in contrast to the two previous reports of single 
matched pairs, which only uncovered support for linear progression in breast cancer metastasis emergence8,9.
Metastasis-to-metastasis seeding is the best fitting evolutionary model considering the available data, how-
ever, alternative evolution routes cannot be definitively excluded. As the complete mass of the primary tumor was 
not sequenced it is possible that the two metastases originated from an undetected subclone within the primary 
tumor.
The main difference between the linear and parallel progression model is the timing of dissemination from the 
primary tumor as continuous genome evolution within a cancer cell population entail that the primary tumor will 
evolve further after early dissemination of a parallel progression metastasis founder cell. Thus, from a mutational 
point of view, the question is whether a metastasis is seeded from the most advanced clone of the primary tumor. 
However, it is important to stress that different selection processes act on primary tumor and metastatic cells, 
as tumorigenic and metastatic features are not identical. Rather, selective forces are timing and site dependent. 
Metastasis can be viewed as an evolutionary process in itself and different genes are believed to be involved in 
different steps of the metastatic process23. Thus, the most advanced clone of the primary tumor is not necessarily 
the one to give rise to metastases, which is in agreement with our results.
Early acquired mutations, present in all malignant cells in copy number neutral regions are expected to pres-
ent a mutation allele frequency around tumor purity x 0.5. This pattern is in fact present in the frequency plots, 
based on point mutation data inferred from deep sequencing data. Alternative estimates, based on Bubble Tree 
analysis, inferred from exome sequencing data, and visualized by the blue arrows in Figs 1–3 in most cases sup-
port this. The Bubble Tree analysis becomes inaccurate at very low tumor purity levels and therefore overestimate 
the diploid heterozygous level in a few cases.
The phylogenetic trees of clonal evolution presented here are inferred from the mutational frequency based 
on deep sequencing data and our conclusions are based on copy number neutral heterozygous positions. Notably, 
the purifying effect seen from one sample to the next, i.e. subclonally occurring mutations in one sample that are 
seen to be purified to constitute complete events in the consecutive tumor step are informative of the subclonal 
origin of metastases.
For P8, P46 and P123 the availability of the ductal carcinoma in situ (DCIS) allowed us to trace back the 
evolution of the primary tumor and consecutive metastases to a subclone already emerging at the stage of this 
precursor lesion. Clonal heterogeneity was found in most tumor samples. The fact that the mutations found exclu-
sively in the aDM of P4, P8, P11 and the sALN of P46 occur subclonally reveal that mutations of the metastasis 
founder cell from the primary tumor were sufficient to establish the metastatic lesion, but that metastasis-specific 
mutations may confer additional clonal advantages, e.g. hypoxia resistance or angiogenesis.
To our knowledge, we present the first evidence of seeding of a distant metastasis from a lymph node metasta-
sis in breast cancer, in accordance with the very recent observations in prostate cancer. Thus, breast cancer metas-
tases may emerge via three different routes: linear progression with late dissemination from the primary tumor, 
early dissemination of the metastasis founder cell leading to parallel progression of primary tumor and metastasis 
and importantly, metastasis-to-metastasis seeding. The genetic disparity between different metastases within the 
same patient and metastasis-to-metastasis seeding in breast cancer has profound clinical implications with regard 
to therapeutic strategies and emphasizes the potential relevance of circulating tumor cell and circulating tumor 
DNA-based surveillance. Our study reveals diverse models of metastasis among patients and even within indi-
vidual patients and emphasize that we have yet to arrive at a complete understanding of the metastatic process.
Materials and Methods
Patient material. The study includes successive tumor samples from six breast cancer patients with estrogen 
receptor (ER) positive invasive ductal carcinoma. Supplementary Table S1 displays clinical information of the 
patients. All patients had synchronous axillary lymph node (sALN) metastases at the time of diagnosis and mate-
rial from primary tumors and sALN metastases from five of the patients were secured during primary surgery 
and stored at − 80 °C until sample preparation. In three cases, also pre-invasive stages, Ductal Carcinoma in Situ 
(DCIS) were secured during primary surgery. In one case, we had access to two different regions of DCIS (P8) and 
www.nature.com/scientificreports/
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in one case, two different regions of primary tumor (P4). In spite of adjuvant therapy, four of the patients experi-
enced recurrence of the disease, with a median relapse time of 3.08 years, and asynchronous metastases were biop-
sied from bone, lymph node and in two cases liver, respectively. Haematoxylin-eosin sections of all tissue samples 
were reviewed by a certified pathologist, ensuring the diagnosis. A start amount of 20–30 mg fresh frozen tissue 
(asynchronous metastasis 5 mg) was used for the purification process. Tissue disruption and homogenization 
was performed using TissueLyser (Qiagen) and purification of DNA was performed using AllPrep DNA/RNA 
Mini Kit (Qiagen). Matched normal tissue and the primary tumor of PT ID 8 were stored as formalin-fixed par-
affin-embedded (FFPE) tissue. The FFPE blocks were cut in 30–40 sections of 10 μ m and DNA extracted using 
AS1000 Maxwell 16 (Promega, USA).
Parts of the analysis of P8 have previously been described in ref. 9.
Ethics statement. Informed consent was obtained from all patients. All experimental protocols were 
approved by the Ethical Committee of Region Syddanmark and notified to the Danish Data Protection Agency. 
The methods were carried out in accordance with the approved guidelines.
Library construction and exome sequencing. One microgram of genomic DNA from each sample was 
randomly fragmented by focused acoustic shearing (Covaris inc.) according to Illumina’s protocol. The fragment 
length was measured by Bioanalyzer (Agilent Technologies 2100), confirming a fragment length of 150–300 bp. 
Exome enrichment was performed with Illumina’s TruSeq DNA Sample Preparation. Paired end sequencing of 
2 × 100 bases was performed on the Illumina HiSeq 1500 platform. FASTQ files were aligned to the human ref-
erence genome GRCh37 (feb. 2009) using the Novoalign v. 3 algorithm (www.novocraft.com) at default param-
eters. Removal of duplicate reads, recalibration and local realignment around indels were performed using Best 
Practices pipeline v. 2.724. The result was a mean coverage rate in the exome region of 11–155×(Supplementary 
Table S2).
Detection of putative somatic mutations. Detection of putative somatic mutations for deep sequencing. 
On the exome sequencing data, somatic variant calling was performed using nine publicly available somatic 
variant callers: EB Call25, Mutect26. Seurat27, Shimmer28, Indelocator (http://www.broadinstitute.org/cancer/cga/
indelocator), Somatic Sniper29. Strelka30, Varscan 231 and Virmid32. All putative somatic mutations reported by 
at least one somatic variant caller, except positions in intronic, intergenic, downstream and non-coding RNA 
intronic areas, were used to select chromosomal candidate regions for targeted deep sequencing.
Targeted deep sequencing of candidate regions. Target enrichment was performed using SureSelect DNA enrichment 
methodology (Agilent). A custom SureSelect enrichment kit was designed using the Agilent SureDesign appli-
cation. Library construction and SureSelect enrichment were performed according to manufacturer’s protocol 
and sequenced on the Illumina HiSeq 1500 platform with paired end sequencing 2 × 100 bases. Deep sequencing 
resulted in a mean coverage of 200–613× of the targeted positions (Supplementary Table S3). Alignment and data 
preprocessing were performed as described above. Variant calling were performed using Varscan 231 version 2.3.6 
(multisample setting). For each patient the following criteria were used: normal sample B Allele Frequency (BAF) 
less than 0.02, all samples should have a read depth of min. 50× and BAF in one of the tumor samples should be 
0.05 at minimum. For positions meeting those criteria, a mutation found with a BAF of 0.025 at minimum was 
included in other tumor samples with if read depth exceeded 200× . The variants were annotated with Annovar 
and only exonic and splicing variants were included for further analysis. Known SNPs with a population allele 
frequency > 1% were excluded.
Subsequently, all identified somatic mutations in the coding region were manually curated, by visual inspec-
tion of the BAM files to remove false positive calls. Variants located in a repetitive area and variants located in 
SNV clusters were excluded, as they most likely result from systematic misalignment. Furthermore, unrelated 
BAM files were compared to the patient BAM files in order to identify error prone regions.
Data presentation. Variant allele frequency plots based on targeted deep sequencing data were created revealing 
the timing and distribution of mutations occurring during progression. Each tumor sample was compared to 
previous steps of progression. In spite of varying degrees of normal cell admixture, the frequency plots allow dis-
tinction between different clusters of mutations. The phylogenetic trees of the clonal evolution models represent 
the most likely explanation. A threshold of at least two mutations was set to define a new subclone.
Estimation of tumor purity and establishment of the 2n heterozygous allele level. To estimate tumor cell content, 
tumor ploidy, allele-specific copy number and clonality we utilized the bioinformatics framework Bubble Tree16 
which presents the data as intuitive graphs (Supplementary Figs S2–S21). The analysis is based on the exome 
sequencing data and takes both copy number variation and germline heterozygous SNP data into account.
Based on the resulting purity estimates, the level corresponding to the diploid, heterozygous allele frequency 
was added to the variant allele frequency plots (Figs 1–3), indicated by an arrow, which makes the BAF measure-
ments between the samples more comparable.
Microarray. DNA from tumor samples of P4 were analyzed using Affymetrix Cytoscan HD array (Affymetrix, 
inc. Santa Clara, CA, USA), (Supplementary Figs S22 and S23). Data analysis on the array data was performed 
using the Nexus 7.5 software (Biodiscovery).
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